APPENDIX 4C ASX: CHM Chimeric Therapeutics Limited ACN 638 835 828 Quarter Ended 3 0 June 202 6 ASX ANNOUNCEMENT 31 July 2026 QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDING 30 JUNE 2026 Sydney, Australia, 31 July 2026: Chimeric...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 13 pages · English
Release
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- Investor Presentation
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
Later from Chimeric Therapeutics
- Application for quotation of securities - CHM
- Trading Halt
- CHM ceases enrolment in Phase 1 trial and Company update
- Appendix 4E and Preliminary Final Report
- FY2026 Annual Report, creditor update and Board changes
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics